TABLE 2.

Lipid-lowering statin therapy decreases LDL-associated LPA

	Patient 1	Patient 2	Patient 3
Total plasma cholesterol (μM)
Pre-	249.86	47.50	79.82
Post-	173.13	33.81	10.05
Percent reduced	30.71%	28.82%	87.41%
LDL cholesterol (μM)
Pre-	84.50	20.06	33.93
Post-	40.30	9.09	0.89
Percent reduced	52.3%	54.69%	97.39%
VLDL/LDL-LPA (all species, pmol)
Pre-	65.54	60.42	16.44
Post-	42.93	15.33	8.35
Percent reduced	34.49%	74.63%	49.2%
HDL/albumin-LPA (all species, pmol)
Pre-	91.31	71.30	87.09
Post-	73.10	57.95	16.27
Percent reduced	19.94%	18.72%	81.32%
Total-LPA (all species, pmol)
Pre-	161.86	90.79	110.93
Post-	119.91	75.16	27.38
Percent reduced	25.91%	17.21%	75.32%

Measurements of LPA were made in whole plasma or isolated lipoprotein fractions from three individuals before (Pre-) and after (Post-) initiation of lipid-lowering statin drug therapy. One hundred microliters of plasma were fractionated and LPA levels in plasma or the individual lipoprotein fractions are normalized to this value.